ST-246

SIGA Technologies · Phase 1 active Small molecule

Tecovirimat (ST-246), developed by SIGA Technologies, is an antiviral drug primarily used for treating monkeypox. It has completed several Phase 2 and 3 trials, with ongoing studies assessing its efficacy and safety. Despite no FDA label, it shows promise in treating orthopoxvirus infections.

At a glance

Generic name	ST-246
Also known as	Tecovirimat
Sponsor	SIGA Technologies
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ST-246 CI brief — competitive landscape report
ST-246 updates RSS · CI watch RSS
SIGA Technologies portfolio CI